© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
November 01, 2007
Liposomal doxorubicin received FDA approval for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.